Associated Papers
Saturation profiling of drug-resistant genetic variants using prime editing.
Kim Y et al.
Nature Biotechnology, 2025
Oncogene-Driven Non-Small Cell Lung Cancers in Patients with a History of Smoking Lack Smoking-Induced Mutations.
Huang CY et al.
Cancer Research, 2024
38587551 (PubMed )
Supplement: can-23-2551_supplementary_tables_suppst.xlsx › Table.S11
Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes.
Zhao W et al.
Bmc Medicine, 2023
36829178 (PubMed )
Supplement: 12916_2023_2768_MOESM1_ESM.docx
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
36830579 (PubMed )
Supplement: biomolecules-13-00210-s001.zip › biomolecules-2098784-supplementary.xlsx › Table_S2
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
37168365 (PubMed )
Supplement: Table_3.xlsx › EGFR_mutations
Relationship between driver gene mutations and clinical pathological characteristics in older lung adenocarcinoma.
Liu X et al.
Frontiers in Oncology, 2023
38023198 (PubMed )
Supplement: Table_1.xlsx › Table_S2
Status of 10 targeted genes of non-small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution.
Li D et al.
Thoracic Cancer, 2020
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
DiBardino DM et al.
Clinical Lung Cancer, 2016
Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
Drilon A et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2015
High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
Sun PL et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2012
Tumor Mutation Signature Reveals the Risk Factors of Lung Adenocarcinoma with EGFR or KRAS Mutation.
Wang J et al.
Cancer Control : Journal of the Moffitt Cancer Center, 0
39760242 (PubMed )
Supplement: sj-xlsx-2-ccx-10.1177_10732748241307363.xlsx › Asian
Select a paper to view details